Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MTRAC update glitazone advice

The Midlands Therapeutics Review and Advisory Committee (MTRAC) has issued updated advice for pioglitazone (Actos®) and rosiglitazone (Avandia®).

The pioglitazone review places this drug as having weaker evidence and having a lower place in therapy. It is suitable for restricted prescribing in primary care because of conflicting evidence in the long-term clinical effects of this drug on cardiovascular outcomes.

The rosiglitazone review recommends that this drug should not be prescribed in primary care because of "inadequate evidence of safety and/or efficacy".

Action: Current recommendations still stand. Metformin continues to be the first choice oral hypoglycaemic with a sulphonylurea added in as second line. This is based upon a proven record of efficacy and safety.

Share 'MTRAC update glitazone advice' on Email Share 'MTRAC update glitazone advice' on Delicious Share 'MTRAC update glitazone advice' on Digg Share 'MTRAC update glitazone advice' on Facebook Share 'MTRAC update glitazone advice' on Google+ Share 'MTRAC update glitazone advice' on reddit Share 'MTRAC update glitazone advice' on StumbleUpon Share 'MTRAC update glitazone advice' on Twitter

atomic-wealth

No Comments to “MTRAC update glitazone advice”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,524 spam comments.

atomic-wealth
fond-illness
summer